. Author manuscript; available in PMC: 2012 Jul 27.

Published in final edited form as: Prostate. 2011 May 31;72(3):253–269. doi: 10.1002/pros.21427

TABLE VII.

Mean Serum-PSAP Values in Age-Adjusted Study Subjects with Normal or Malignant Prostate

Age	Normal	Primary PCa		Metastatic CRPCa^*	P-value^†
Age	Normal	pT2	pT3	Metastatic CRPCa^*	P-value^†
40–49 (n=16)	72.0 ± 6.64 (n=9)	74.0 ± 30.18 (n=1)	45.2 ± 10.74 (n=4)	81.3 ± 20.52 (n=2)	0.2403
50–59 (n=47)	77.7 ± 3.48 (n=11)	48.2 ± 6.74 (n=27)	27.3 ± 4.48 (n=10)	88.7 ± 11.85 (n=6)	0.0001
60–69 (n=60)	70.6 ± 2.80 (n=17)	34.7 ± 3.37 (n=27)	33.7 ± 5.42 (n=8)	107.0 ± 7.54 (n=8)	0.0001
70–79 (n=31)	87.5 ± 8.94 (n=7)	51.4 ± 7.62 (n=10)	79.0 ± 15.33 (n=1)	114.9 ± 8.15 (n=13)	0.0003
N	44	58	23	29
Mean ± SE	75.4 ± 16.4	43.0 ± 24.64	34.9 ± 18.82	105.0 ± 28.43
Median (Min, Max)	73.4 (46.1, 123.0)	32.0 (7.8, 99.0)	25.2 (13.2, 79.0)	101.7 (55.4–154.6)

CRPCa, Castrate-resistant prostate cancer

^†

P-value corresponds to the slice test for each age group after finding the non-significant interaction (p=0.1434); mean PSAP levels differ among normal individuals and PCa patients in all age group except for the youngest age group (p=0l.2403). Malultiple comparisons were performed using ANOVA and Tukey-Kramer procedure to maintain an overall significance of 0.05.